Treatment of Primary Axillary Hyperhidrosis with Botulinum Toxin Type A: Our Experience in 50 Patients from 2007 to 2010. (17th October 2012)

• Record Type: Journal Article
• Authors: Scamoni, Stefano; Valdatta, Luigi; Frigo, Claudia; Maggiulli, Francesca; Cherubino, Mario
• Other Names: Saga K. Academic Editor.; Shenefelt P. D. Academic Editor.
• Is Part Of: ISRN dermatology. Volume 2012(2012)
• Publication Date: 2012-10-17
• Subjects: Dermatology -- Periodicals; Skin Diseases; Dermatology; Dermatology; Periodicals; 616.5
• DOI: 10.5402/2012/702714
• Languages: English
• ISSNs: 2090-4592

Abstract

Abstract : Background . Local injections of Botulinum toxin type A (BTX-A) are an effective and safe solution for primary bilateral axillary hyperhidrosis. Traditional treatments are often ineffective and difficult to tolerate. This study was performed to assess the efficacy and safety of Botulinum toxin type A in the treatment of these diseases and to evaluate the reliability of patient's subjective rating in the timing of repeat injections. Methods . From 2007 to 2008, we included in the study and treated a total of 50 patients, and we used the Minor's iodine test and the hyperhidrosis diseases severity scale as initial inclusion criteria and also for evaluating the followup, comparing to patient's subjective rating. We used also a specific questionnaire to evaluate the level of pain, the onset of the effect, any eventual adverse effect of the treatment, the onset of compensatory hyperhidrosis, and the global grade of satisfaction. The data were analyzed using standard statistical methods. Results . 88% of patients were totally satisfied and all patients repeated the treatment during all the study. The symptom-free interval was in median 6 months with an average improving of HDSS of 1.5 points. In 86%, there was a complete accordance between the subjective patient's demand of the repetition of the treatment and the positivity to Minor test and HDSS. No major side effects happened. Conclusion . Local injections of Botulinum toxin type A (BTX-A) result in an effective and safe solution for bilateral axillary primary hyperhidrosis for the absence of significant morbidity, side effects, and lack of efficacy or duration. The only defects are the need of repetition of the treatment and relative costs.